CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CAMP4 Therapeutics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CAMP4 Therapeutics Corp
One Kendall Square
Bldg 1400 West 3rd Floor
Phone: (617) 651-8867p:617 651-8867 CAMBRIDGE, MA  02139  United States Ticker: CAMPCAMP
Business Summary
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Steven H.Holtzman 70 10/1/2019 10/1/2019
President, Chief Executive Officer, Director JoshMandel-Brehm 41 1/1/2017 1/1/2017
Chief Financial Officer KellyGold 47 4/1/2022 1/1/2017
6 additional Officers and Directors records available in full report.

Business Names
Business Name
CAMP
CAMP4 THERAPEUTICS CORPORATION
CAMP4 Therapeutics Pty Ltd

General Information
Number of Employees: 58 (As of 6/30/2024)
Outstanding Shares: 19,505,119 (As of 6/30/2024)
Stock Exchange: NASD
Fax Number: (302) 655-5049
Email Address: info@camp4tx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024